Galecto Biotech Revenue and Competitors
Estimated Revenue & Valuation
- Galecto Biotech's estimated annual revenue is currently $9.3M per year.
- Galecto Biotech's estimated revenue per employee is $169,091
- Galecto Biotech's current valuation is $62.4M. (January 2022)
Employee Data
- Galecto Biotech has 55 Employees.
- Galecto Biotech grew their employee count by -25% last year.
Galecto Biotech's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Finance | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
Galecto Biotech Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Galecto Biotech?
Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. Galecto is funded by Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure and SEED Capital.
keywords:N/A
N/A
Total Funding
55
Number of Employees
$9.3M
Revenue (est)
-25%
Employee Growth %
$62.4M
Valuation
N/A
Accelerator
Galecto Biotech News
Galecto Reports Completion Of Enrollment In Phase 2b GALACTIC-1 Trial Of GB0139 For Treatment Of Idiopathic Pulmonary Fibrosis.
Other Companies in Copenhagen
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.2M | 55 | -19% | N/A |
#2 | N/A | 55 | 22% | N/A |
#3 | $7.2M | 55 | 34% | N/A |
#4 | $10.4M | 55 | -23% | N/A |
#5 | $7.2M | 55 | -7% | N/A |